Macrostemonoside I alleviates metabolic dysfunction-associated steatotic liver disease in mice: potential involvement of SCAP/SREBP2 signaling in cholesterol metabolism.
4 affiliations
- 1Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, China.
- 2Department of Geriatrics, 900th Hospital of PLA Joint Logistic Support Force, Fuzhou, China.
- 3Outpatient Department, 900th Hospital of PLA Joint Logistic Support Force, Fuzhou, China.
- 4Department of Gastroenterology, 900th Hospital of PLA Joint Logistic Support Force, Fuzhou, China.
Abstract
The progression of metabolic dysfunction-associated steatotic liver disease (MASLD) involves lipotoxicity and inflammation from disordered cholesterol metabolism. Macrostemonoside I (MI), an Allium saponin monomer, may regulate cholesterol metabolism, but its role in MASLD is unclear. MASLD was induced in mice by a 6-week choline-deficient high-fat diet (CDAHFD) (1-week gradual transition to CDAHFD and 5 weeks of continuous CDAHFD feeding), followed by treatment with MI (2, 4, 8 mg/kg/d), atorvastatin, or vehicle for 30 days. Body weight, liver index, serum levels of HDL-C, ALT, AST and inflammatory cytokines were measured. Hepatic cholesterol content, histopathology (H&E, Oil Red O, Sirius red, Immunofluorescent staining), oxidative stress markers, transcriptome and the expression of genes/proteins related to cholesterol metabolism and fibrosis were analyzed. MI reduced liver index, ameliorated hepatic ballooning and steatosis, and decreased hepatic total cholesterol and free cholesterol, as well as serum ALT/AST levels, but had no significant effect on HDL-C. It reduced hepatic CD11b⁺ infiltration and serum IL-1β, IL-6, TNF-α levels. Liver fibrosis area, and the fibrosis markers COL1A1 and α-SMA, were downregulated. MI also decreased hepatic ROS and MDA, and increased SOD activity. Furthermore, MI treatment was associated with changes in the cholesterol transcriptome and with significant reductions in both the mRNA and protein levels of the cholesterol metabolism-related molecules SCAP and SREBP2. MI might alleviate MASLD by reducing cholesterol accumulation, suppressing inflammation, ameliorating fibrosis, and mitigating oxidative stress, potentially via SCAP/SREBP2 pathway. However, causality remains to be determined.
Related
- Commentary: Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis
- Endoplasmic Reticulum Autophagy Enhancement Alleviates Synaptic Plasticity Dysfunction and Ameliorates Cognitive Impairment in SAE Mice by Relieving STING‐Associated Inhibition of PKM2 Activity
- Liver Dysfunction Assessed by Albumin – Bilirubin (ALBI) Score is Associated with Disturbed Cholesterol Profiles and Reduced Survival in Patients with Chronic Limb-Threatening Ischemia
- Monocyte-to-high-density lipoprotein cholesterol ratio and carotid atherosclerosis in patients with metabolic dysfunction-associated steatotic liver disease: a comparative analysis of systemic inflammatory indices.
- Harpagide alleviates neuroinflammation and cognitive dysfunction in sepsis-associated encephalopathy: Association with the MMP9/NF-κB signaling pathway
BibTeX
@article{su2026macrostemonoside,
title = {{Macrostemonoside I alleviates metabolic dysfunction-associated steatotic liver disease in mice: potential involvement of SCAP/SREBP2 signaling in cholesterol metabolism.}},
author = {Jiyuan Su and Shouyu Lin and Chuanshen Jiang and Huimin Lin and Yunhua Yu and Wen Wang},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1983132},
url = {https://europepmc.org/article/MED/42952792},
note = {CC BY},
}
RIS
TY - JOUR
TI - Macrostemonoside I alleviates metabolic dysfunction-associated steatotic liver disease in mice: potential involvement of SCAP/SREBP2 signaling in cholesterol metabolism.
AU - Jiyuan Su
AU - Shouyu Lin
AU - Chuanshen Jiang
AU - Huimin Lin
AU - Yunhua Yu
AU - Wen Wang
PY - 2026
DA - 2026/10/14
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1983132
UR - https://europepmc.org/article/MED/42952792
AB - The progression of metabolic dysfunction-associated steatotic liver disease (MASLD) involves lipotoxicity and inflammation from disordered cholesterol metabolism. Macrostemonoside I (MI), an Allium saponin monomer, may regulate cholesterol metabolism, but its role in MASLD is unclear. MASLD was induced in mice by a 6-week choline-deficient high-fat diet (CDAHFD) (1-week gradual transition to CDAHFD and 5 weeks of continuous CDAHFD feeding), followed by treatment with MI (2, 4, 8 mg/kg/d), atorvastatin, or vehicle for 30 days. Body weight, liver index, serum levels of HDL-C, ALT, AST and inflammatory cytokines were measured. Hepatic cholesterol content, histopathology (H&E, Oil Red O, Sirius red, Immunofluorescent staining), oxidative stress markers, transcriptome and the expression of genes/proteins related to cholesterol metabolism and fibrosis were analyzed. MI reduced liver index, ameliorated hepatic ballooning and steatosis, and decreased hepatic total cholesterol and free cholesterol, as well as serum ALT/AST levels, but had no significant effect on HDL-C. It reduced hepatic CD11b⁺ infiltration and serum IL-1β, IL-6, TNF-α levels. Liver fibrosis area, and the fibrosis markers COL1A1 and α-SMA, were downregulated. MI also decreased hepatic ROS and MDA, and increased SOD activity. Furthermore, MI treatment was associated with changes in the cholesterol transcriptome and with significant reductions in both the mRNA and protein levels of the cholesterol metabolism-related molecules SCAP and SREBP2. MI might alleviate MASLD by reducing cholesterol accumulation, suppressing inflammation, ameliorating fibrosis, and mitigating oxidative stress, potentially via SCAP/SREBP2 pathway. However, causality remains to be determined.
SN - 2296-858X
ER -